ClinicalTrials.gg
CompletedNCT07697157Updated Jul 13, 2026

The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate Tablets

A Phase 1 interventional study of HMPL-453 with Itraconazole and HMPL-453 with Rifampin in Health, Subjective, sponsored by Hutchmed. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Hutchmed · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Primary objective:

  1. To evaluate the effect of Itraconazole ( CYP3A and P-gp inhibitors) on HMPL-453 pharmacokinetics(PK) in healthy subjects
  2. To evaluate the effect of Rifampin (CYP enzyme inducer) on HMPL-453 pharmacokinetics (PK) in healthy subjects

Secondary objectives:

To evaluate the safety of HMPL-453 with and without itraconazole or rifampin following a low-fat meal in healthy subjects

Exploratory objectives:

  1. Assess cholesterol and 4β- hydroxycholesterol in plasma CYP3A4 Biomarker Concentration Levels ;
  2. Explore proarrhythmic effect of HMPL-453 [Results of exploratory objectives analyses will be reported separately and not included in the clinical trial Study Report (CSR)]
02

Conditions studied

  • Health, Subjective
03

In context

Lead sponsor

Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has fully understood and voluntarily signed the ICF for this study.
  2. Male or female 18 years of age or older.
  3. (BMI) at screening: 18 \< BMI ≤ 29.9 kg/m 2 and weight ≥ 50 kg for men and ≥ 45 kg for women.
  4. Female subjects of use highly effective from 1 month prior to signing ICF through 6 months following the last HMPL-453 dose and agree not to donate ova for reproductive purposes during this period (or oocytes). Acceptable forms of highly effective contraception include total abstinence, bilateral tubal ligation, oral or injectable contraceptives, intrauterine devices, or vasectomy in the partner. All hormonal contraception must be combined with barrier measures such as condom use by the spouse.
  5. Male subjects agree to use highly effective contraception from first dose until 3 months after the last HMPL-453 dose. Subjects should refrain from donating or freezing sperm during this period .
  6. Subject is willing and able to comply with the protocol in all aspects.

Exclusion criteria

Exclusion Criteria:

  1. Patients with previous or excluded diseases with abnormal clinical manifestations during the screening period, including but not limited to neurological/psychiatric system, respiratory system, cardiovascular and cerebrovascular system, gastrointestinal system (any history of gastrointestinal diseases affecting oral or absorption of drugs), blood and lymphatic system, liver and kidney function, endocrine system, and immune system diseases.
  2. Subjects with (eg, requiring medical intervention or surgical treatment) disease within 8 weeks or clinically significant (requiring systemic anti-infective treatment, such as oral or intravenous antiviral, antibacterial, antifungal therapy, etc) infection within 4 weeks prior to the first dose.
  3. Subject has a current or past history of retinal detachment.
  4. Use of any medications (including prescription drugs, over-the-counter drugs, herbal preparations and formulas, etc.) and health products within 2 weeks prior to the first dose.
  5. Hypericum perforatum requiring 4 weeks or 5 half-lives (whichever is longer) prior to first dose 3 weeks) Use of any drugs that inhibit or induce cytochrome P450 enzymes or P- glycoprotein inhibitors (See Appendix 12.3 for details).
  6. Subject has received blood or blood products 4 weeks prior to first dose and donated blood or blood products 8 weeks prior to first dose.
  7. Subjects who cannot guarantee not to take any food, juice or beverage containing alcohol, grapefruit, Seville oranges and caffeine within 72 hours prior to the first dose until the end of the trial; and have special requirements for diet and cannot comply with the unified diet.
  8. Smoking more than 10 cigarettes per day within 3 months prior to screening and unable to completely abstain from smoking during the study.
  9. Regular drinkers 6 months prior to screening, defined as drinking more than 14 units of alcohol per week ( 1 units = 360 mL Beer or 45 mL spirits or 150 mL wine containing 40% alcohol; positive alcohol screen.
  10. Participated in other clinical trials of drugs or medical devices 3 months before taking study drug, or failed online screening.
  11. Fainting, halo, or difficulty collecting venous blood.
  12. Subject is hypersensitive to any of the study medications (or their ) administered in this study.
  13. Female subject is pregnant or lactating, or has a positive pregnancy test result.
  14. The subject had clinically significant abnormalities in physical examination, abdominal B scan (hepatobiliary pancreatic splenorenal), and laboratory test results at Screening.
  15. Abnormal vital signs (excluded if any of the following: systolic blood pressure:

    \< 90 mmHg or > 140 mmHg , diastolic blood pressure: \< 60 mmHg or > 90 mmHg ; pulse: \< 60 beats

    /min or > 100 beats/min; Body temperature \< 35.8 ° C or > 37.3 ° C (frontal temperature).

  16. Subjects with keratopathy confirmed by ophthalmic examination, including but not limited to bullous keratopathy, band keratopathy, corneal abrasion, corneal ulcer, keratitis, or other ophthalmic abnormalities considered by the investigator as inappropriate for participation in this study.
  17. The subject had clinically significant abnormalities, including a prolonged baseline (eg, QTcF interval > 450 ms in males and QTcF interval > 460 ms in females), or a family history of QTc prolongation syndrome or sudden death. If ECG does not show QTcF results, use the following formula for calculation: QTcF = QT/RR .
  18. Presence of drug abuse (including morphine, methylenedioxyamphetamine, methylamphetamine, tetrahydrocannabinolic acid, ketamine, cocaine urine drug abuse screen positive) at Screening.
  19. (HIV) antibody, surface antigen (HBsAg), virus Positive (HCV) antibody or syphilis-specific antibody.
  20. Abnormal chest X-ray (anteroposterior) findings with clinical significance (such as active infection, high-risk nodules, etc.).
  21. Any other condition that, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Other
    Part A:HMPL-453 with Itraconazole

    Drug: HMPL-453 with Itraconazole

  • Other
    Part B:HMPL-453 with Rifampin

    Drug: HMPL-453 with Rifampin

Interventions

  • DrugHMPL-453 with Itraconazole

    Drug pages: Fanregratinib · Itraconazole

    HMPL-453: 100mg, D1、D14; Itraconazole: 400mg, D10;200mg,D11-D22

  • DrugHMPL-453 with Rifampin

    Drug pages: Fanregratinib · Rifampin

    HMPL-453: 300mg, D1、D16; Rifampin: 600mg, D10-D24

06

What researchers measure

Primary outcomes

  1. AUC 0-t

    Area under the plasma concentration - time curve from time 0 to time of last measurable concentration

    Time frame: 25Days

  2. AUC 0- ∞

    Area under the plasma concentration - time curve from time 0 extrapolated to infinity

    Time frame: 25Days

  3. C max

    Peak concentration

    Time frame: 25Days

Secondary outcomes

  1. T max, t 1/2

    Additional PK parameters of HMPL-453 , such as time to maximum concentration (T max), terminal elimination half-life (t 1/2), etc.

    Time frame: 25Days

  2. AE rate

    Incidence, severity, seriousness and relatedness of adverse events (AEs), laboratory test results, vital signs, physical examination, 12 lead electrocardiogram (ECG), ophthalmologic examination, etc.

    Time frame: through study completion, an average of 33days

07

Study locations

1 site
  • yijishan Hospital
    Wuhu, Anhui 241000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Dec 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Jul 13, 2026
StartActual
Mar 1, 2025
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07697157
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Mar 1, 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Jul 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fanregratinib · Itraconazole · Rifampin

Start the discussion